Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 19/20 | 0.75 |
| ▸ | ESR2 | Q92731 | 16/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11547729 | 0.95 | ESR1 (0.68) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL11552368 | 0.94 | ESR1 (0.75) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL1665657 | 0.92 | ESR1 (0.86) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL11547449 | 0.90 | CNR1 (0.64) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL11550840 | 0.88 | CNR1 (0.71) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL8631942 | 0.86 | ESR1 (0.81) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL8562371 | 0.86 | ESR1 (0.76) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL8626952 | 0.86 | ESR1 (0.80) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL31683627 | 0.86 | ESR1 (0.81) | ESR1ESR2MEN1KMT2ATDP1 | |
| SCHEMBL7104864 | 0.86 | ESR1 (1.00) | ESR1ESR2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0819686-B1 | Benzothiophene compounds, and uses and formulations thereof | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | claimed |
| US-5972888-A | LOWERING THE PRODUCTION OR RELEASE OF NEUROPEPTIDE Y WHICH COMPRISES ADMINISTERING TO A MAMMAL IN NEED THEREOF AN EFFECTIVE AMOUNT OF AN ISOLATED NATURALLY OCCURRING OBESITY PROTEIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ELI LILLY AND COMPANY (US) | 1999-10-26 | — | — | US | claimed |
| US-5780648-A | Benzothiophene compounds, and uses formulations thereof | ELI LILLY AND COMPANY (US) | 1998-07-14 | — | — | US | claimed |
| EP-0819686-A1 | Benzothiophene compounds, and uses and formulations thereof | ELI LILLY AND COMPANY (US) | 1998-01-21 | — | — | EP | claimed |
| US-20070099876-A1 | Target directed chemotherapy of tumours of the sexual organs | TRIN GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| US-20070099876-A1 | Target directed chemotherapy of tumours of the sexual organs | TRIN GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
| EP-0819686-B1 | Benzothiophene compounds, and uses and formulations thereof | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | disclosed |
| US-5827876-A | MODIFYING BALANCE BETWEEN BONE RESORPTION AND PRODUCTION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-10-27 | — | — | US | disclosed |
| US-5780648-A | Benzothiophene compounds, and uses formulations thereof | ELI LILLY AND COMPANY (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0819686-A1 | Benzothiophene compounds, and uses and formulations thereof | ELI LILLY AND COMPANY (US) | 1998-01-21 | — | — | EP | disclosed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099876-A1 | Target directed chemotherapy of tumours of the sexual organs | GPER1, SHBG, GNRHR | ESR1 4/4885ESR2 5/4885MEN1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.